This is in line with the study published by Latva-Rasku and colleagues, which demonstrated that 8-week treatment with dapagliflozin does not affect tissue insulin sensitivity and MGU as measured with PET in T2D patients [25], but contrasts with other studies which instead described an increase in insulin sensitivity [26–28]. This evidence concerns the gene INS and type 2 diabetes mellitus.